CN104013816A

CN104013816A - Pharmaceutical composition for treating esophagus cancer

Info

Publication number: CN104013816A
Application number: CN201410280157.4A
Authority: CN
Inventors: 李绍松
Original assignee: Individual
Current assignee: Individual
Priority date: 2014-06-20
Filing date: 2014-06-20
Publication date: 2014-09-03

Abstract

The invention discloses a pharmaceutical composition for treating an esophagus cancer. The pharmaceutical composition is prepared from the following raw materials in parts by weight: 20-30 parts of nightshade, 20-30 parts of solanum lyratum thumb, 20-30 parts of duchesnea indica, 20-30 parts of radix sophorae tonkinensis, 20-30 parts of rhizoma belamcandae, 20-30 parts of fruticose dracaena leaves, 12-24 parts of radix cynanchi panicullati, 12-24 parts of sculellaria barbata, 12-24 parts of hedyotis diffusa, 12-24 parts of pangolin scales, 12-24 parts of rabdosia rubescens, 12-24 parts of calomel, 12-24 parts of airpotato yam, 12-24 parts of manyleaf paris rhizome and 12-24 parts of indian iphigenia bulb which are used as active ingredients. The invention also discloses a pharmaceutical composition with a good treatment effect on the esophagus cancer and use thereof.

Description

A kind of pharmaceutical composition for the treatment of esophageal carcinoma

Technical field

The present invention relates to technical field of Chinese medicines, be specifically related to a kind of pharmaceutical composition for the treatment of esophageal carcinoma.

Background technology

Cancer (Cancer), also claims malignant tumor (Malignant neoplasm), serves as reasons and controls the not normal and disease that causes of growth and proliferation of cell mechanism.Cancerous cell except grow out of control, arround also can local invading, normal structure is even transferred to other parts of health via body-internal-circulation system or lymphsystem.Cancer is the general designation of a large class malignant tumor.The feature of cancerous cell be unrestrictedly, hypertrophy without end, the nutrient substance in patient body is consumed in a large number; Cancerous cell discharges multiple toxin, makes human body produce series of symptoms; Cancerous cell also can be transferred to whole body growth and breeding everywhere, cause that human body is become thin, unable, anemia, inappetence, heating and serious organ function impaired etc.Cancer (malignant tumor) also can disorganize, the 26S Proteasome Structure and Function of organ, causes downright bad hemorrhage concurrent infection, and patient is finally dead due to organ failure.

The esophageal carcinoma is common digestive tract tumor, and the whole world approximately has 300,000 people to die from the esophageal carcinoma every year.Its M & M various countries are widely different.China is one of Esophageal Cancer area in the world, every annual approximately 150,000 people that die of illness.Man is more than female, and age of onset is many more than 40 years old.The typical symptom of the esophageal carcinoma is carrying out property acataposis, and the food of difficult dry pharynx, was semiliquid diet then before this, and last water and saliva can not be swallowed.

At present, treatment cancer, doctor trained in Western medicine generally adopts operation, chemotherapy, radiotherapy, and the toxic and side effects that Radiotherapy chemotherapy produces is to human body infringement greatly, patient often can not get satisfied effect, but causes on the contrary the adverse consequencess such as health immunologic hypofunction.In early days, cancer can reach by operation the object of healing in conjunction with the method for Chinese medicine; But arrived the late period of cancer, operation method has been difficult to reach the object of healing, can only treat by chemicotherapy or with Chinese medicine.For avoiding western medical treatment defect, in China medical circles once someone released the scheme that treats with herbal composite treatment cancer.Chinese traditional treatment cancer is approved by domestic and international Medical Technologist now widely, the effect of Chinese traditional treatment cancer that a large amount of clinical trials and scientific research are verified.As the patent of invention of Chinese patent CN102526630B, disclose a kind of Chinese medicine that is used for the treatment of esophageal carcinoma, it comprises: Radix Clematidis, Nidus Vespae, Herba Pyrolae, Flos Inulae, Fructus Gleditsiae Abnormalis, Thallus Laminariae (Thallus Eckloniae), Fructus Trichosanthis, Rhizoma Acori Graminei, Herba Dendrobii, Herba Centipedae, Herba Schizonepetae, Fructus Aurantii Immaturus, the Radix Linderae, Radix Rubiae, Pseudobulbus Bletillae (Rhizoma Bletillae), Rhizoma Curcumae Longae, Radix Salviae Miltiorrhizae, Lignum Sappan, Rhizoma Sparganii, Concha Ostreae, Haematitum, the Radix Astragali, the Rhizoma Atractylodis Macrocephalae, Radix Et Caulis Acanthopanacis Senticosi, the Radix Paeoniae Alba and Caulis Spatholobi.Current also useful Indigo Naturalis, Calomelas are applied in the research report of cancer, but the traditional Chinese medical science is to have no limits to the research of cancer, develops very necessary for the Traditional Chinese medicine composition of cancer.

Summary of the invention

The technical problem to be solved in the present invention is to provide a kind of good pharmaceutical composition of esophageal carcinoma effect for the treatment of.

In pharmaceutical composition of the present invention, the consumption of each component is that inventor draws through a large amount of practice summaries, by the raw material of following weight parts, is made:

Preferably, it is to be made by weight by following raw materials according:

More preferably, it is to be made by weight by following raw materials according:

The medically acceptable dosage forms such as the preferred pill of dosage form of pharmaceutical composition of the present invention, tablet, dispersible tablet, their preparation method, supplementary product consumption are undertaken by existing common process.

The present invention also comprises the application of aforementioned pharmaceutical compositions in preparation treatment esophageal cancer medicine.

In pharmaceutical composition prescription of the present invention:

Herba Solani Nigri--Cheongju thermal detoxification, inducing diuresis to remove edema, various cancerous protuberance effect;

Herba Solani Lyrati--clearing away heat-damp and promoting diuresis, subduing swelling and detoxicating, anticancer swollen effect;

Herba Duchesneae Indicae--heat-clearing and toxic substances removing, cooling blood for hemostasis, broken tumor, cancer effect;

Radix Sophorae Tonkinensis--heat-clearing and toxic substances removing, relieving sore throat and diminishing swelling effect;

Rhizoma Belamcandae--relieving cough and resolving phlegm, removing dampness, logical lung

Folium cordylines fruticosae--damp eliminating removing heat from blood, softening the hard mass tumor, evacuation of pus effect;

The Chang Township of Xu--promoting the circulation of QI to relieve pain, promoting blood circulation and detoxication, anticancer swollen effect;

Herba Lobeliae Chinensis--diuretic, subduing swelling and detoxicating effect;

Herba Hedyotidis Diffusae--heat clearing away solution is swollen, anticancer swollen effect;

Squama Manis--promoting blood circulation to restore menstrual flow, detumescence and apocenosis effect;

Rabdosia rubescens--heat-clearing and toxic substances removing, anticancer swollen,

Calomelas--life removing the necrotic tissue, anticancer swollen effect;

Rhizoma Dioscoreae Bulbiferae--reducing swelling and alleviating pain, suppuration, anticancer swollen effect;

Rhizoma Paridis--promoting blood circulation and stopping pain, circulation of qi promoting evacuation of pus, antitumaous effect;

Pseudobulbus Cremastrae Seu Pleiones--eliminating stagnation, reduce phlegm, detoxify, control the effect of swelling and ache.

Pharmaceutical composition of the present invention is at Calomelas on the basis as anticancer pharmaceutical composition, add other components, compare simple use Calomelas, there is anti-cancer and detumescence, antiviral, anticancer spreads diffusion fast, intercept cancerous cell and destroy each organ dysfunction, repair esophagus inwall, improve unique curative effect of immunologic function.

The specific embodiment

With specific embodiment, the invention will be further described below, but the present invention is not limited to these embodiment.

Embodiment 1

Above-mentioned raw materials is smashed, crossed 80 mesh sieves, add making pellets by mixing medical powder with honey, obtain pill.

Embodiment 2

Above-mentioned raw materials is mixed, pulverized 80 mesh sieves, obtain powder.

Embodiment 3

By proportional quantity, take above each raw material, decoct with water twice, add for the first time 7 times of water gagings, decoct 1.5 hours, add for the second time 8 times of water gagings, decoct 1.5 hours, collecting decoction, filters, and filtrate is concentrated into relative density be 1.30 extractum of (70 ℃ time survey), add appropriate cane sugar powder, routinely the agent of technique granulation.

Embodiment 4

By proportional quantity, take above each raw material, decoct with water twice, add for the first time 7 times of water gagings, decoct 1.5 hours, add for the second time 8 times of water gagings, decoct 1.5 hours, collecting decoction, filters, filtrate is concentrated into relative density be 1.30 extractum of (70 ℃ time survey), the magnesium stearate adjuvant that adds conventional amount used, technique is made tablet routinely, 0.5 part/sheet of specification.

Embodiment 5

By proportional quantity, take above each raw material, decoct with water twice, add for the first time 7 times of water gagings, decoct 1.5 hours, add for the second time 8 times of water gagings, decoct 1.5 hours, collecting decoction, filters, filtrate is concentrated into relative density be 1.30 extractum of (70 ℃ time survey), add the magnesium stearate adjuvant of conventional amount used, make capsule, 0.5g/ grain.

Experimental example: the inhibitory action of pharmaceutical composition of the present invention to cancerous cell

1, experiment material: the pharmaceutical composition of the embodiment of the present invention 3, embodiment 5 preparations.

Experiment place: the Guangxi Qinzhou hospital of traditional Chinese hospital.

2, tumor cell line: human esophagus cancer cell Eca-109, use RPMI-1649 culture fluid, 37 ℃, 5%C0 ₂, relative humidity 100% is cultivated, and attached cell 0.25% trypsinization goes down to posterity.

3, the inhibitory action of method MTT colorimetric method for determining extract to growth of tumour cell.The trophophase cell of taking the logarithm, is mixed with cell suspension with fresh RPMI-1640 culture fluid, suspension cell 1X10 ⁵individual/ml attached cell 0.8X10 ⁵individual/ml.Suspension cell is inoculated in 96 well culture plates after adding respectively variable concentrations Experimental agents; Attached cell is first inoculated in 96 well culture plates, and every hole 90 μ l, add respectively variable concentrations Experimental agents after 24h.Final volume is that every hole 100 μ l and every group are established 3 parallel holes, establishes altogether 4 groups: be subject to reagent group T (culture fluid+cell suspension+variable concentrations is subject to reagent), negative control group N (culture fluid+cell suspension), medicine color matched group TC (culture fluid+variable concentrations is subject to reagent), blank group B (culture fluid+normal saline).Tested concentration is followed successively by 10 μ part/m1,30 μ part/m1,50 μ part/ml.Put 37 ℃, 5%C0 ₂in incubator, cultivate after 72h, after adding the 10 μ l concussions of MTT solution to mix to every hole, continue to cultivate 4h, add SDS90 μ l to stop cultivating, 37 ℃ are spent the night, then under room temperature, on micro oscillator, shake 10min, microplate reader is measured the absorbance (OD value) at 570nm wavelength place, and experiment repeats 3 times.

Calculate as follows growth inhibition ratio:

Growth inhibition ratio (%)=[(N group OD average-B group OD average)-(T group OD average-TC group OD average)]/[N group OD average-B group OD average] X100%.

4, medicine the results are shown in Table 1 to the suppression ratio of human esophagus cancer cell Eca-109.

Table 1: the suppression ratio result to Eca-109

Result shows, the pharmaceutical composition of embodiment 3, embodiment 5 preparations has inhibitory action to the propagation of Eca-109 cell, and embodiment 5 curative effects are better than embodiment 3.

Clinical effectiveness

For many years, medicine composite for curing esophageal carcinoma of the present invention clinical observation, all obtains promising result, is now reported as follows:

1, physical data

107 routine patients all hitch institute and out-patient, male 66 people, women 41 people, the oldest 77 years old, minimum 35 years old; The course of disease is the longest 3 years, the shortest half a year.

2, diagnostic criteria

Selecting tcm diagnosis esophageal carcinoma is standard:

Symptom generally had sternal region malaise symptoms, occasionally had burn feeling or a pain phenomenon morning of esophageal carcinoma, mid-term, in the time of on the feed, there are foreign body sensation or friction sense in part, sometimes swallowing food has at a certain position and stagnates or slight sense of obstruction, and the hypomere esophageal carcinoma can also cause under xiphoid-process or epigastric discomfort, contrary, heating installation.

The symptom in late period of esophageal carcinoma is obvious is exactly mainly to occur dysphagia on the feed time, block, have pain phenomenon, occasionally have that massive hemorrhage, patient's sound become hoarse, weight loss serious and occur anorexia phenomenon.

Take the capsule that the embodiment of the present invention 5 obtains, every day 3 times, each 2,30 days courses for the treatment of, take 3 courses for the treatment of.

3, criterion of therapeutical effect

Effective: esophageal carcinoma transference cure, it is normal that body constitution is recovered, and observes half a year without recidivist;

Effective: esophageal carcinoma shape is clearly better, and body constitution is progressively recovered;

Invalid: disease is unchanged, tumor tumor body increases, or newborn tumor is found at other position.

4, therapeutic outcome

Claims

1. a pharmaceutical composition for the treatment of esophageal carcinoma, is characterized in that: this pharmaceutical composition is to be made by the raw material of following weight parts:

。

2. the pharmaceutical composition for the treatment of esophageal carcinoma according to claim 1, is characterized in that: this pharmaceutical composition is to be made by the raw material of following weight parts:

。

3. the pharmaceutical composition for the treatment of esophageal carcinoma according to claim 1, is characterized in that: this pharmaceutical composition is to be made by the raw material of following weight parts:

。

4. the application of the pharmaceutical composition described in any one in the medicine of preparation treatment esophageal carcinoma in claim 1-3.